I Rhythm Technologies, Inc. IRTC
We take great care to ensure that the data presented and summarized in this overview for iRhythm Technologies, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IRTC
View all-
Vanguard Group Inc Valley Forge, PA3.12MShares$266 Million0.0% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI2.78MShares$237 Million0.32% of portfolio
-
Black Rock Inc. New York, NY2.5MShares$213 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA2.12MShares$181 Million0.5% of portfolio
-
Capital Research Global Investors Los Angeles, CA1.96MShares$167 Million0.03% of portfolio
-
Mackenzie Financial Corp Toronto Ontario, A61.42MShares$121 Million0.16% of portfolio
-
Alliancebernstein L.P. New York, NY1.21MShares$103 Million0.03% of portfolio
-
Jpmorgan Chase & CO New York, NY940KShares$80 Million0.01% of portfolio
-
State Street Corp Boston, MA909KShares$77.4 Million0.0% of portfolio
-
Braidwell LP Stamford, CT783KShares$66.7 Million1.65% of portfolio
Latest Institutional Activity in IRTC
Top Purchases
Top Sells
About IRTC
iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
Insider Transactions at IRTC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 02
2024
|
Patrick Michael Murphy CBO and CLO |
SELL
Open market or private sale
|
Direct |
2,492
-6.59%
|
$211,820
$85.89 P/Share
|
|
Nov 04
2024
|
Abhijit Y Talwalkar Director |
BUY
Open market or private purchase
|
Direct |
6,664
+26.03%
|
$499,800
$75.16 P/Share
|
|
Nov 04
2024
|
Quentin S. Blackford President and CEO |
SELL
Open market or private sale
|
Direct |
16,145
-9.17%
|
$1,243,165
$77.41 P/Share
|
|
Aug 09
2024
|
Brice Bobzien Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,372
-5.32%
|
$96,040
$70.34 P/Share
|
|
Aug 02
2024
|
Mervin Smith EVP Strategic Business Ops |
SELL
Open market or private sale
|
Direct |
688
-6.23%
|
$50,912
$74.66 P/Share
|
|
Aug 02
2024
|
Chad Patterson Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,012
-7.5%
|
$222,888
$74.66 P/Share
|
|
Jul 02
2024
|
Minang Turakhia EVP, CMO & CSO |
SELL
Open market or private sale
|
Direct |
1,404
-4.9%
|
$147,420
$105.65 P/Share
|
|
Jun 03
2024
|
Sumi Shrishrimal EVP, Chief Risk Officer |
SELL
Open market or private sale
|
Direct |
1,131
-4.63%
|
$99,528
$88.91 P/Share
|
|
Jun 03
2024
|
Marc W. Rosenbaum Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
510
-5.87%
|
$44,880
$88.91 P/Share
|
|
May 31
2024
|
Quentin S. Blackford President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
280
+0.16%
|
$20,720
$74.98 P/Share
|
|
May 31
2024
|
Chad Patterson Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
280
+0.69%
|
$20,720
$74.98 P/Share
|
|
May 29
2024
|
Bruce G. Bodaken Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,841
+14.03%
|
-
|
|
May 29
2024
|
Merz Cathleen Noel Bairey Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,841
+19.47%
|
-
|
|
May 29
2024
|
Ralph Snyderman Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,841
+13.37%
|
-
|
|
May 29
2024
|
Mojdeh Poul Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,841
+30.27%
|
-
|
|
May 29
2024
|
Abhijit Y Talwalkar Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,841
+13.04%
|
-
|
|
May 29
2024
|
Mark J Rubash Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,841
+12.9%
|
-
|
|
May 29
2024
|
Brian B Yoor Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,841
+30.27%
|
-
|
|
May 29
2024
|
Karen Ling Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,841
+18.32%
|
-
|
|
Mar 04
2024
|
Brice Bobzien Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,401
-5.15%
|
$155,511
$111.14 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 179K shares |
|---|---|
| Open market or private purchase | 6.94K shares |
| Open market or private sale | 86.3K shares |
|---|